Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid 1

Interventions

Imatinib Mesylate 15Dasatinib 14nilotinib 8olverembatinib 4asciminib 4ponatinib 3Cyclosporine 3bosutinib 2Methotrexate 2Homoharringtonine 2Cyclophosphamide 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2inecalcitol 1flumatinib 1fludarabine phosphate 1elsulfavirine 1Whole-Body Irradiation 1Transplantation 1Radiotherapy 1Peripheral Blood Stem Cell Transplantation 1PF-114 1Mycophenolic Acid 1Interferon-alpha 1Hydroxyurea 1Fentanyl 1Everolimus 1Cytarabine 1Cord Blood Stem Cell Transplantation 1Busulfan 1BMS-833923 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Myeloid, Chronic-Phase × flumatinib × Clear all
NCT05367765 2022-05-10

A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 4 Not yet recruiting
2,400 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡